Drugs / fluorocholine
fluorocholine
English name 18F-Fluorocholine
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00928174 | Jun 2009 → Jul 2013 | prostate cancer | Queen's Medical Center | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02397408 | Apr → Jun 2015 | prostate cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT01395030 | Aug 2011 → May 2017 | adult hepatocellular carcinoma | Queen's Medical Center | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07444723 | Apr 2026 → Feb 2035 expected | hyperparathyroidism 2 with jaw tumors, multiple endocrine neoplasia, parathyroid gland carcinoma | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03764007 | Sep 2016 → May 2021 | primary hyperparathyroidism | Thomas Hope | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT05622162 | Dec 2022 → Jun 2024 | prostate cancer | ITEL Telecomunicazioni Srl | Unknown | No outcome recorded |
| Phase 3 | NCT04895631 | Jun 2021 → Dec 2025 | primary hyperparathyroidism | Thomas Hope | Completed | No outcome recorded |
| Phase 3 | NCT03891914 | Nov 2019 → Jan 2023 | plasma cell myeloma | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 3 | NCT03623425 | Feb 2019 → May 2020 | prostate cancer | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| Phase 3 | NCT02840552 | Sep 2016 → Feb 2018 | prostate cancer | Sir Mortimer B. Davis - Jewish General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02640313 | Dec 2015 → Mar 2024 | atherosclerosis | Maastricht University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03555487 | May 2015 → Jun 2018 | parathyroid gland disorder | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02074202 | Feb 2014 → Mar 2015 | hepatocellular carcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01956409 | Sep 2012 → Dec 2016 | female breast carcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04340765 | Feb 2018 → Dec 2019 | prostate cancer | Buddhist Tzu Chi General Hospital | Completed | No outcome recorded |
| — | NCT01993160 | Dec 2013 → Dec 2016 | prostate cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07218224 | — | parathyroid gland adenoma | Thomas Hope | Available | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fluorocholine | “with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions” NCT03891914 ↗ |
| Known as | 18F choline | “18F-choline has shown increased sensitivity when compared with 18-FDG, with about 75% more lesions detected in patients with relapsed or progressive multiple myeloma (MM).” PMID 32909953 ↗ Sep 20203“11C or 18F choline is a PET probe used in imaging prostate cancer and hepatocellular carcinoma.” NCT03555487 ↗ |
| Known as | 18F-FCH | “18F-Fluoromethylcholine (18F-FCH) PET/CT” NCT02840552 ↗5“Fluorocholine (18F-FCH) Injection” NCT01993160 ↗ |
| Known as | 18F-Fluorocholine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07218224 ↗ |
| Known as | 18F-fluorocholine (fluoromethyl-(2-hydroxyethyl)-dimethylazanium) | “18F-fluorocholine (fluoromethyl-(2-hydroxyethyl)-dimethylazanium)” NCT07218224 ↗ |
| Known as | 18F-fluoromethylcholine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01395030 ↗ |
| Known as | Fluorine F 18 Choline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02397408 ↗ |
| Known as | Fluorine f 18 fluoromethylcholine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303280 ↗ |
| Known as | fluorine-18 fluorocholine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00928174 ↗ |
| Known as | FLUOROCHOLINE F-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303280 ↗ |
| Known as | Fluoromethylcholine f-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303280 ↗ |
| Known as | Iasocholine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303280 ↗ |
| Modality | Diagnostic / imaging agent | “using fluorine-18 fluorocholine as an imaging agent” NCT00928174 ↗ |
| Route | Intravenous | “Fluorine-18 fluorocholine IV” NCT00928174 ↗ |